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Thrombocytopenia in HIV can at times be a very challenging illness 
to treat, mainly because of its multifactorial aetiology. The astute 
practitioner should be aware of all these possibilities so that the 
necessary tests are done initially and the correct treatment started. 
Knowledge of megakaryocyte physiology helps to understand the 
condition.
Thrombopoiesis
The exact mechanisms of thrombopoiesis are still not fully 
understood. We know that between 1 000 – 3 000 platelets are 
derived from a megakaryocyte, and that 30 000 - 45 000 platelets/
µl/day are produced in the normal bone marrow. We also know that 
there is a physiological reserve that allows our marrow to increase 
production 6-fold. It has become apparent that megakaryocyte 
morphology plays an important role in thrombopoiesis and that 
large megakaryocytes produce more platelets than smaller ones. 
The higher the ploidy (nuclear lobulation), the higher the platelet 
production (preferably a ploidy > 8). Fig. 1 depicts a normal 
megakaryocyte. 
The mechanisms that control platelet size are poorly understood 
but it seems that the body tries to maintain the total platelet mass 
and not the total platelet count. The total platelet mass is the 
constant derived when multiplying the total platelet count by 
the mean platelet volume. When the platelet count decreases, the 
mean platelet volume increases. When megathrombocytes (giant 
platelets) are seen on the peripheral smear it usually indicates 
peripheral consumption of platelets. There is evidence that large 
platelets can be produced by large and small megakaryocytes and 
that these large platelets may be more active than smaller ones.
Thrombopoietin
Thrombopoietin is a molecule that is produced in the liver at 
a constant steady state. Its ligand, C-Mpl, is found on platelets, 
megakaryocytes, stem cells and other immature cells in the bone 
marrow. Thrombopoietin stimulates stem cells to differentiate 
into megakaryocytes, prevents apoptosis in megakaryocytes and 
stimulates megakaryocytes to proliferate in number, size and 
ploidy. It will also stimulate peripheral platelets and makes them 
sticky.
Once thrombopoietin binds with its ligand it is internalised and 
will then through secondary messenger systems, JCK and STAT, 
cause its effects. If there is a normal or increased peripheral platelet 
count, most of the thrombopoietin will bind to the peripheral 
platelets, leaving little to bind with cells in the marrow. However 
if the peripheral platelet count is low, more thrombopoietin will 
enter the marrow and bind with marrow cells, thereby stimulating 
the marrow to increase its output. As mentioned earlier, this output 
can be increased to a maximum of 6-fold. The incidence of diseases 
such as hepatitis B and C is increasing within the HIV-infected 
community and can severely hamper thrombopoietin production, 
due to liver damage.
HIV and platelets
Thrombocytopenia in HIV was first described in 1982. The 
prevalence is more or less 40%, depending on which literature is 
quoted. Thrombocytopenia is associated with increased morbidity 
and mortality, accelerated deterioration in CD4 counts and 
accelerated progression to full-blown AIDS.1 In a meta-analysis 
of 5 trials involving > 3 000 patients, both treatment-naïve and 
treatment-experienced patients, thrombocytopenia was found to 
be one of 8 factors that correlated with a poorer prognosis and 
more rapid progression to full-blown AIDS in spite of antiretroviral 
treatment.1
A recent study showed that platelets have the ability to ‘engulf ' the 
HI virus and Staphylococcus aureus – perhaps another reason why 
thrombocytopenia is prone to a more rapid acceleration of disease. 
Severe thrombocytopenia also limits one’s treatment options, 
as many drugs cause bone marrow suppression and peripheral 
platelet consumption.
Other authors have maintained that there is a causal relationship 
between Haemophilus pylori infection and thrombocytopenia in 
HIV and insist on eradication therapy as part of their treatment 
strategy. This association has however not been reproducible in 
other centres.
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Thrombocytopenia in HIV is challenging and difficult to treat.
NEIL LITTLETON, MB ChB, MMed (Int Med)
Head, Department of Haematology, Provincial Hospital, Port Elizabeth
Neil Littleton did his internal medicine training at Tygerberg Hospital, and his subspecialisation at Tygerberg and Groote Schuur hospitals. In the past 
year he moved to Port Elizabeth and created a Department of Haematology. His special interests are lymphoma, particulary HIV-associated lymphoma 
in HIV, and the bone marrow.
272
Fig. 1. A normal megakaryocyte.
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HIV enters the megakaryocytes and 
platelets via the CXCR4 receptors. Once 
the virus is in the megakaryocyte it starts 
to cause havoc, as shown by the change 
in megakaryocyte morphology. The 
following are common signs of HIV in the 
bone marrow: 
•  dysplasia in the bone marrow
•   naked nuclei or bare nuclei – apoptotic 
megakaryocytes
•  hypolobation of the nuclei 
•   tendency to form discrete separate 
nuclear lobules 
•  clustering of the megakaryocytes. 
Fig. 2 depicts a dysplastic megakaryocyte.
Platelets have the tendency to shed their 
epitopes and can ‘donate’ their CXCR4 
receptors to CD4null and CXCR4null 
cells, e.g. cardiac muscle and astrocytes in 
the brain, thereby allowing these cells to 
be infected.
The gp120 Ab directed towards HIV can 
and does cross-react with the GP111A 
receptor on the platelet, as does the 
P24 Ab. The Ab can be found coated to 
HIV-infected individuals with normal 
platelet counts. Platelet life span is 
decreased in HIV-induced idiopathic 
thrompocytopenic purpura (ITP) and in 
HIV patients without ITP. 
It seems as if HIV stimulates CD5+ cells 
to produce IgM rheumatoid antibodies 
directed against the Fc portion of IgG 
antibodies as well as Ab directed to the 
F(Ab)2 portion of the anti GP111A 
Ab, thereby protecting the platelet. 
Thrombocytopenia early on in HIV is 
mainly due to peripheral destruction, 
while later on in the advanced stage (AIDS) 
it is more likely to be due to decreased 
production. In fact, CD4 counts above 200 
are associated with increased peripheral 
destruction while thrombocytopenia in 
CD4 counts of  < 200 is associated with 
decreased platelet production.
In one study the authors found a 3-fold 
increase in megakaryocytes in patients 
with HIV. However, there was no increase 
in the mean platelet mass, suggesting the 
presence of dysmegakaryopoiesis. This 
suggests that thrombocytopenia in HIV is 
multifactorial because of: 
•   direct HIV infection of the 
megakaryocyte, causing apoptosis
•   dysmegakaryopoiesis, abnormal 
and dysfunctional production of 
megakaryocytes and platelets
•   peripheral destruction of platelets due to 
cross-reactivity of HIV Abs. 
Who to treat
This is probably one 
of the most difficult 
questions to answer 
along with ‘how 






and there is a paucity 
of forthcoming trials 
on this topic since 
antiretrovirals have 
become commonly 
used. Most trials 
available are small, 
uni-centre, non-RCT, and do not include 
triple therapy, only AZT monotherapy.
The generally accepted guideline is to 
treat when there are < 30 000 platelets 
or < 50 000 if the patient is on warfarin 
or a haemophiliac.6 One must still 
remember that thrombocytopenia 
correlates with a poorer outcome and 
accelerated HIV course and at least a 2-
fold increase in mortality. In opposition 
to this, treatment of thrombocytopenia 
is immunosuppressive in its nature and 
therefore should be given in conjunction 
with antiretrovirals. If this is early on in 
the disease, it may cause problems with 
long-term compliance or with the local 
centres providing antiretrovirals, because 
they are subjected to dogmatic criteria 
from the DOH. A platelet count of 50 
post-treatment is quite acceptable for 
protection against bleeding, but still does 
predict a poorer outcome with regards to 
mortality and morbidity.
Therefore thrombocytopenia occurs as a 
result of:
•  increased peripheral destruction or
•  increased peripheral sequestration or
•  decreased production or
•  a combination of the above.
Table I lists drugs that directly 
affect thrombopoiesis. The causes of 
thrombocytopenia are listed in Table II.
Approach to 
management 
As with any other patient, start with a 
good history. Try to ascertain how long the 
problem has been going on and the clinical 
severity. It is also of value to find out about 
recent infections, any recent medications 
taken and any traditional medicines. A 
full blood count is recommended with a 
peripheral smear, as well as antinuclear 
factor, syphilis serology and if the 
diagnosis of HIV has just been made, then 
viral load and CD4 counts. The policy in 
my department and of most other centres 
is to do a bone marrow biopsy, to asses 
megakaryocyte numbers and morphology. 
One can then easily exclude granulomas, 
Kaposi’s sarcoma and lymphoma or even 
fibrosis in the marrow. It is policy in 
my department to do a TB culture with 
every marrow done on an HIV-positive 
individual.
Once the decision is made to treat, then 
the difficulty is deciding how to treat.
Steroids 
A dose of 1 mg/kg/day prednisone should 
be started as a first-line therapy. Monitor 
the platelet counts regularly and be alert 
for opportunistic infections. If no response 
is seen within a 2-week period, one can try 
a higher dosage of 2 mg/kg/day. This is the 
dosage used in the HIV-negative cohort. 
These patients should be monitored 
carefully and be on antiretrovirals. Patients 
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•  Amphotericin B
•  Indinavir
•  Ritonavir
Fig. 2. A dysplastic megakaryocyte.
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should not stay on high-dosage therapy 
for more than a month. If no response 
or a nominal response is seen, it should 
be considered as treatment failure and 
alternative treatment given. I find it most 
risky to keep patients on low-dose steroids 
for protracted periods of time, due to the 
side-effects and the immunosuppresion.
Prednisone does not stimulate viral 
replication but does however accelerate 
the course of Kaposi’s sarcoma.2
Intravenous 
immunoglobulin 
Intravenous immunoglobulin (IVIG) 
is effective in raising a patient’s platelet 
counts. However, it is not cheap and 
results can be timeous and short lasting. It 
is not a cost-effective way of maintaining a 
platelet count and should only be used in 
chronic cases as a last resort. In the acute 
setting it is good for raising counts prior to 
a splenectomy or if patients have severe or 
uncontrollable haemorrhage. This would 
then be used in conjunction with platelet 
transfusions. The exact mechanisms of 
action are not entirely understood – suffice 
to say that excessive immunoglobulin 
(Ig) overwhelms the immune system 
and stimulates the suppressor B cells to 
suppress endogenous Ig production. The 
IVIG also blocks the Fc receptors in the 
spleen and macrophages, thereby limiting 
their platelet-destroying function. The 
dosage of the IVIG can differ from 0.5 g/kg 
to 2 g/kg either as a bolus but mostly given 
over 2 - 5 days. The cost and availability of 
IVIG are the most limiting factors.
Anti-D 
The anti-rhesus globulin can also be used 
with varying success. This should not be 
used in patients who are Rh+ as it may 
cause haemolysis. It can however be used 
if the patient has a normal haemoglobin. 
Its effects, if there is going to be a response, 
are said to be longer lasting than IVIG.
Splenec tomy 
Splenectomy is the usual 2nd-line of 
therapy with the HIV-negative cohort. 
There were concerns initially that it would 
accelerate the course of HIV. This was before 
antiretroviral therapy was commonly 
available. At the moment, besides the 
concerns of infections from capsulated 
organisms and malaria, splenectomy may 
be a good alternative.3 The literature has 
shown splenectomy to attenuate immune 
reconstitution syndrome and has shown 
to produce patients with a higher CD4 
and CD8 counts along with a slower 
progression to AIDS. 
Splenic irradiation is of no value in this 
situation.
Megestrol acetate 
This drug was initially used to treat 
cachexia and anorexia in HIV. It is known 
to block the Fc receptors in macrophages. 
Trials have shown that megestrol acetate 
(MA) increases peripheral platelet counts 
and improves platelet survival. There were 
no improvements in body mass index 
(BMI), peripheral CD4 counts or viral 
loads.
Danazol is still of value in idiopathic 
thrombocytopenic purpura, even in HIV-
induced ITP.4
Transfusions 
Transfusions have a transient effect, they 
are expensive and should be limited to 
emergencies and theatre. Normally they 
should be given with IVIG to have a longer 
lasting effect. Transfusions have other side-
effects, e.g. transfusion reactions, infections 
and transfusion-related acute lung injury 
(TRALI). Multiple transfusions are known 
to decrease immunity and stimulate HIV-
1 expression.
Novel therapies 
These are still in experimental phases 
but include entities such as recombinant 
thrombopoietin, alpha interferon and Il-6, 





This is a severe haemolytic disorder 
characterised by fragmentation of the red 
cells, low platelets and purpura. In severe 
and neglected cases renal impairment and 
cerebrovascular signs are seen. The basic 
pathophysiology is due to a deficient or 
dysfunctional protease ADAMTS-13. This 
protease cleaves the large von Willebrand 
molecules into smaller molecules, allowing 
haemostasis to occur. This disease is 
seen in the HIV-negative and positive 
cohorts. It can be seen as part of a sero-
conversion disease but is mostly seen 
in the later stages of HIV with low CD4 
counts. This disease is very common in 
South Africa and unfortunately still has 
a high mortality and morbidity, probably 
due to underdiagnosis, misdiagnosis and 
maltreatment. 
There are various treatment options for this 
condition, ranging from plasma exchange, 
vincristine and cryoglobulin-poor fresh 
Transfusions have a transient effect, 
they are expensive and should be 
limited to emergencies and theatre.
Table II. Causes of thrombocytopenia 
Decreased production
•  Haematinic deficiencies, e.g. folate vit B12
•   Dysmegakaryopoiesis (direct HIV infection, drugs, cytokines from other infections 
or malignancies, etc.)
•  Direct infections of the bone marrow
•  Malignancies infiltrating the bone marrow
•  Amegakaryopoiesis, hereditary causes (May-Hegglin, etc.)
•  Drugs: delavirdine and nelfinavir (see Table I)
Peripheral consumption
•  Idiopathic thrombocytopenic purpura
•  Diffuse intravascular coagulopathy
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frozen plasma (FFP) with prednisone 
1 mg/kg/day. The effectiveness of using 
cryo-poor FFP and prednisone is similar 
to plasma exchange and is a practical and 
viable alternative treatment option for 
caregivers in the rural settings.5 At least 
treatment can be initiated locally and the 
patient stabilised before transferring to a 
main centre. 
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In a nutshell 
•  Thrombocytopenia in HIV is common and multifactorial. 
•  Normal megakaryocyte morphology is important to maintain normal thrombopoiesis.
•   Thrombocytopenia early on in the disease is generally due to peripheral destruction and 
has large platelets, while in AIDS it is usually associated with decreased production.
•   Thrombocytopenia, irrespective of cause and concomitant antiretroviral therapy, is as-
sociated with a poorer outcome and accelerated decrease in CD4 counts and AIDS pro-
gression.
•   An initial bone marrow biopsy is mandatory to asses the thrombopoiesis, among other 
things, along with CD4 count and viral load.
•   Consider starting antiretrovirals when active treatment is decided on, especially when 
using immunosuppressive agents.
•   DO NOT leave patients on steroids for protracted periods without antiretroviral cover and 
be vigilant for opportunistic infections.
•   Always consider thrombotic thrombocytopenic purpura as a cause of thrombocytopenia 
in HIV.
•   If no plasma exchange facility is available or if one chooses not to use it, always use cryo-
precipitate-poor FFP, along with steroids and start antiretrovirals.
•  When in doubt, refer and leave the decision of splenectomy to specialists.
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